DBV Technologies | DBVT

Stock Price
8.97
Daily Change
-0.25 -2.75%
Monthly
-9.16%
Yearly
124.12%
Q3 Forecast
8.90

Peers Price Chg Day Year Date
Acadia Pharmaceuticals 25.26 -0.24 -0.94% 57.19% Sep/05
Alnylam Pharmaceuticals 452.00 -1.54 -0.34% 83.16% Sep/05
Amarin 15.33 0.30 2.00% 27.64% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
DBV Technologies 8.97 -0.25 -2.75% 124.12% Sep/05
Halozyme Therapeutics 74.93 1.53 2.08% 26.55% Sep/05
Incyte 86.64 1.20 1.40% 41.43% Sep/05
Insmed 145.10 2.57 1.80% 104.25% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
PTC Therapeutics 57.26 -0.75 -1.29% 81.55% Sep/05
Ultragenyx Pharmaceutical 31.82 0.54 1.73% -42.40% Sep/05
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
United Therapeutics 400.52 20.05 5.27% 15.88% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05

DBV Technologies traded at $8.97 this Friday September 5th, decreasing $0.25 or 2.75 percent since the previous trading session. Looking back, over the last four weeks, DBV Technologies lost 9.16 percent. Over the last 12 months, its price rose by 124.12 percent. Looking ahead, we forecast DBV Technologies to be priced at 8.90 by the end of this quarter and at 8.71 in one year, according to Trading Economics global macro models projections and analysts expectations.

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.